Research Advances of EGFR-TP53 Co-mutation in Advanced Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2022.101.06
- Author:
Rong WANG
1
;
Sisi PAN
2
;
Xia SONG
1
Author Information
1. The Second Department of Respiratory, Shanxi Provincial Cancer Hospital, Taiyuan 030000, China.
2. The Second Clinical Medical College of Shanxi Medical University, Taiyuan 030000, China.
- Publication Type:Review
- Keywords:
Co-mutation;
Epidermal growth factor receptor;
Lung neoplasms;
TP53;
Therapy
- MeSH:
Carcinoma, Non-Small-Cell Lung/genetics*;
ErbB Receptors/genetics*;
Humans;
Lung Neoplasms/genetics*;
Mutation;
Protein Kinase Inhibitors/therapeutic use*;
Tumor Suppressor Protein p53/genetics*
- From:
Chinese Journal of Lung Cancer
2022;25(3):174-182
- CountryChina
- Language:Chinese
-
Abstract:
With the rapid development and wide application of next generation sequencing (NGS) technology, a series of researches have revealed that concurrent genetic alterations play an important role in the response and resistance of epidermal growth factor receptor (EGFR)-mutant NSCLC to EGFR-tyrosine kinase inhibitor (TKI). Besides, TP53 mutation is the most common co-mutation gene in EGFR-mutant NSCLC, which has been proved to confer a worse prognosis in EGFR-mutated patients treated with first, second and third generation of EGFR-TKIs. Currently, it is still being explored how to select the best treatment strategies for patients with concomitant presence of TP53 mutation in EGFR-mutant NSCLC. Here, we review the literature on recent research progress of TP53 concurrent mutation in EGFR-mutant advanced NSCLC.
.
